関連する実験動画
Updated: Sep 10, 2025

12:04
The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
Published on: November 1, 2015
17.9K
SLEにおける治療から標的までの進歩:臨床的意思決定支援システムを用いた試験試験
Agner R Parra Sánchez1,2, Koen Vos3, Odile van Hall2,4
1Department of Rheumatology and Clinical Immunology, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands a.r.parrasanchez@amsterdamumc.nl.
Lupus science & medicine
|August 22, 2025
まとめ
臨床的意思決定支援システムによる 治療目標戦略の実施は 実現可能であり,利用可能であり,受け入れられるものです このアプローチは,患者の満足度に影響を与えることなく,積極的な治療調整をサポートします.
科学分野:
- 病理学と免疫学
- 医療情報学
- 臨床試験の設計
背景:
- システミック・ルプス・エリテマトーサス (SLE) の管理には,積極的な治療調整が必要である.
- トリートメント・トゥ・ターゲット (T2T) 戦略は,事前に定義された治療目標を達成することによって患者の結果を最適化することを目的としています.
- 臨床的意思決定支援システム (CDSS) は,臨床医が証拠に基づいた治療プロトコルを実装するのに役立ちます.
研究 の 目的:
- SLE 外来治療のT2T戦略の実現性,利用性,受け入れ性を評価する.
- CDSSでサポートされるT2Tアプローチの治療改変と患者の満足度への影響を評価する.
主な方法:
- SLEの成人の患者を対象とした24週間の非ランダム化多中心試験.
- 患者はT2T戦略とCDSS (T2T- CDSS) または通常の診療 (ROC) に割り当てられました.
- 実現可能性 (採用,留守),可用性 (システム可用性スケール),可用性 (治療満足度アンケート,質的フィードバック) を評価した. 探索的アウトカムには,疾患の活動率と寛解率が含まれていました.
主要な成果:
- 募集率は42% (38/91患者) であり,保持率は92% (35/38患者) であった.
- CDSSは良好な可用性を示した (SUSスコア73.8).
- T2T-CDSS群では治療の強化と緩和 (グルココルチコイドの減少) がより頻繁に行われたが,グループ間の疾患活動や寛解の有意な違いは観察されなかった.
結論:
- CDSSでサポートされるT2T戦略の実施は,通常のSLEの外科医のケアでは実現可能であり,利用可能であり,受け入れられます.
- CDSSは,SLEにおける目標指向の治療に希望を示し,主動的でターゲット指向の治療調整を容易にする.
- 将来の大規模な試験に際して 実施の障壁を解決することが重要です
関連する概念動画
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Drug Discovery: Overview
8.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.7K
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Targets for Drug Action: Overview
7.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.4K
Structure-Activity Relationships and Drug Design
1.0K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.0K

